Literature DB >> 24395655

Diagnostic value of alpha-L-fucosidase for hepatocellular carcinoma: a meta-analysis.

Yuling Gan1, Qiuzhen Liang, Xinghua Song.   

Abstract

Alpha-fetoprotein (AFP) is the primary marker for detecting hepatocellular carcinoma (HCC) and has been used widely in the clinic, but AFP is a biomarker characterized by poor sensitivity and specificity. Alpha-L-fucosidase (AFU) has been proposed as a tumor marker for diagnosis of HCC in many studies. However, conclusions of its diagnostic value are inconsistent. The current review aimed to evaluate the diagnostic value of AFU for HCC. After systematic review of 12 related studies, sensitivity, specificity, and diagnostic odds ratio (DOR) were pooled using random-effect models. Summary receiver operating characteristic (sROC) curve analysis was used to summarize the overall test performance. The pooled sensitivity for AFU was 0.72 (95% confidence interval (CI) 0.69-0.76), while the pooled specificity was 0.78 (95% CI 0.74-0.81). DOR was 10.26 (95% CI 5.99-17.59), and the area under the curve (AUC) was 0.8125. AFU had great value for the diagnosis of HCC as a serum marker.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24395655     DOI: 10.1007/s13277-013-1563-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  37 in total

1.  The abnormalities of lysosomal enzymes in mucopolysacc- haridoses.

Authors:  F Van Hoof; H G Hers
Journal:  Eur J Biochem       Date:  1968-12

Review 2.  Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis.

Authors:  Xiaoyan Yi; Shuang Yu; Yixi Bao
Journal:  Clin Chim Acta       Date:  2013-08-13       Impact factor: 3.786

3.  Characterization of alpha-L-fucosidase from two different families with fucosidosis.

Authors:  J Troost; M C van der Heijden; G E Staal
Journal:  Clin Chim Acta       Date:  1976-12-01       Impact factor: 3.786

4.  Activities of serum enzymes in patients with viral hepatitis B, posthepatitic cirrhosis and hepatocellular carcinoma.

Authors:  T Zheng; Z Y Ren
Journal:  Chin Med J (Engl)       Date:  1990-09       Impact factor: 2.628

5.  Serum alpha-L-fucosidase. A more sensitive marker for hepatocellular carcinoma?

Authors:  F Marotta; D H Chui; P Safran; S C Zhang
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

6.  Characterization of cirrhosis and hepatocellular carcinoma using low-angle x-ray scattering signatures of serum.

Authors:  Wael M Elshemey; Omar S Desouky; Mohammed S Mohammed; Anwar A Elsayed; Motawa E el-Houseini
Journal:  Phys Med Biol       Date:  2003-09-07       Impact factor: 3.609

Review 7.  New serum markers of hepatocellular carcinoma.

Authors:  Ryota Masuzaki; Seth J Karp; Masao Omata
Journal:  Semin Oncol       Date:  2012-08       Impact factor: 4.929

8.  Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma.

Authors:  Ken Chen; Hong Zhang; Li-Na Zhang; Shao-Qing Ju; Jing Qi; Dong-Feng Huang; Feng Li; Qun Wei; Jing Zhang
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

Review 9.  Strategies for the management of hepatocellular carcinoma.

Authors:  Myron Schwartz; Sasan Roayaie; Manousos Konstadoulakis
Journal:  Nat Clin Pract Oncol       Date:  2007-07

10.  Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma.

Authors:  Mohamed Fawzy Montaser; Mohamed Amin Sakr; Mohamed Omar Khalifa
Journal:  Arab J Gastroenterol       Date:  2012-04-05       Impact factor: 2.076

View more
  16 in total

1.  Plasma alpha-L-fucosidase activity in chronic inflammation and autoimmune disorders in a pediatric cohort of hospitalized patients.

Authors:  Ildikó Endreffy; Geir Bjørklund; László Szerafin; Salvatore Chirumbolo; Mauricio A Urbina; Emőke Endreffy
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

Review 2.  Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma.

Authors:  Mahmoud Khattab; Magdy Fouad; Elham Ahmed
Journal:  World J Hepatol       Date:  2015-10-18

3.  HCC with low- and normal-serum alpha-fetoprotein levels.

Authors:  Brian I Carr; Hikmet Akkiz; Oguz Üsküdar; Kendal Yalçın; Vito Guerra; Sedef Kuran; Ümit Karaoğullarından; Engin Altıntaş; Ayşegül Özakyol; Salih Tokmak; Tuğsan Ballı; Mehmet Yücesoy; Halil İbrahim Bahçeci; Abdulalh Ülkü; Tolga Akçam; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necati Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Ali Demir; Anıl Delik; Burcu Arslan; Figen Doran; Sezai Yilmaz; Yaman Tokat
Journal:  Clin Pract (Lond)       Date:  2018

4.  Evaluation of the diagnostic value of alpha-l-fucosidase, alpha-fetoprotein and thymidine kinase 1 with ROC and logistic regression for hepatocellular carcinoma.

Authors:  Shi-Yan Zhang; Bi-Ding Lin; Bu-Ren Li
Journal:  FEBS Open Bio       Date:  2015-03-26       Impact factor: 2.693

Review 5.  Serum HER2 Is a Potential Surrogate for Tissue HER2 Status in Gastric Cancer: A Systematic Review and Meta-Analysis.

Authors:  Kecheng Zhang; Jianxin Cui; Hongqing Xi; Shibo Bian; Liangang Ma; Weisong Shen; Jiyang Li; Ning Wang; Bo Wei; Lin Chen
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

6.  Serum AFU, 5'-NT and AFP as Biomarkers for Primary Hepatocellular Carcinoma Diagnosis.

Authors:  Zhu Junna; Chen Gongde; Xu Jinying; Zhou Xiu
Journal:  Open Med (Wars)       Date:  2017-10-11

7.  Alpha-l-fucosidase: a novel serum biomarker to predict prognosis in early stage esophageal squamous cell carcinoma.

Authors:  Xiangyang Yu; Rusi Zhang; Tianzhen Yang; Mengqi Zhang; Kexing Xi; Yongbin Lin; Yingsheng Wen; Gongming Wang; Zirui Huang; Xuewen Zhang; Lanjun Zhang
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

8.  Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.

Authors:  Mahmoud Ma Elsayed; Mahmoud E Mostafa; Eman Alaaeldin; Hatem Aa Sarhan; Montaser ShA Shaykoon; Shady Allam; Ahmed Rh Ahmed; Bakheet Em Elsadek
Journal:  Int J Nanomedicine       Date:  2019-10-29

9.  Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels.

Authors:  Wan-Ju Xu; Bao-Li Guo; Yu-Gang Han; Lei Shi; Wan-Shan Ma
Journal:  Tumour Biol       Date:  2014-09-12

10.  Genetic correction improves prediction efficiency of serum tumor biomarkers on digestive cancer risk in the elderly Chinese cohort study.

Authors:  Ke Wang; Yansen Bai; Shi Chen; Jiao Huang; Jing Yuan; Weihong Chen; Ping Yao; Xiaoping Miao; Youjie Wang; Yuan Liang; Xiaomin Zhang; Meian He; Handong Yang; Qingyi Wei; Huan Guo; Sheng Wei
Journal:  Oncotarget       Date:  2017-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.